Trials / Completed
CompletedNCT03985046
Sintilimab Plus Chemotherapy Followed by dCRT in Locally Advanced ESCC
A Pilot Study of Sintilimab Plus Chemotherapy Followed by Definitive Concurrent Chemoradiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 75 (actual)
- Sponsor
- Fudan University · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to observe and evaluate the efficacy and safety of A sintilimab plus chemotherapy followed by definitive concurrent chemoradiotherapy in locally advanced esophageal squamous cell carcinoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sintilimab plus Chemotherapy | Sintilimab will be administered intravenously, a fixed dose of 200 mg. Paclitaxel 135mg/m2, carboplatin AUC=5. Once every 3 weeks. |
Timeline
- Start date
- 2019-10-10
- Primary completion
- 2021-05-31
- Completion
- 2022-12-31
- First posted
- 2019-06-13
- Last updated
- 2024-11-07
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03985046. Inclusion in this directory is not an endorsement.